These are the 'new' / 'interesting' bits of info I got out of this presentation
- Production capacity for TEMCELL is currently being increased as JCR has received orders far in excess of initial forecasts - this is a different narrative to the manufacturing issues mentioned in BP report, will be interesting to see if there's any further mention on this.
- COVID 19 ARDS trial expected to complete recruitment in Q4FY20 - here's hoping for the positive early readout!
- Post marketing study for aGVhD - planning underway: 'post-marketing' hopefully means they know an FDA approval is coming for paediatric!
- First patient has been treated for MIS-C and has been discharged from the hospital - implies a positive outcome!
- Label extensions for RYONCIL include Bacterial ARDS and Influenza ARDS - large addressable markets
- CHF & CLBP readouts 'expected' Q4FY20 - delays on these are a little frustrating but looks like RYONCIL is the priority
These are the 'new' / 'interesting' bits of...
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.023(1.95%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.19 | $1.15 | $3.024M | 2.584M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 93324 | $1.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 139921 | 49 |
View Market Depth
| Last trade - 13.41pm 23/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |